Interview: Why inhibit Ketohexokinase (KHK) to treat NASH?
MARCH 6, 2019 | DISCOVERY ON TARGET
Kendra K. Bence, PhD, Senior Director, Metabolism, Internal Medicine Research Unit (IMRU), Pfizer, Inc.
Dr. Bence explains why and how Pfizer scientists developed an inhibitor against ketohexokinase as a drug candidate for non-alcoholic steatohepatitis (NASH), a form of liver fibrosis.